This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): MB-003/ZMAb, 13C6/13F6/6D8
Description: ZMapp (MB-003) is composed of three “humanized” monoclonal antibodies manufactured in plants, specifically Nicotiana. It is an optimized cocktail combining the best components of MB-003 (Mapp) and ZMAb (Defyrus/PHAC). This cocktail of monoclonal antibodies targets three separate glycoprotein epitopes displayed on the ebola viral envelope and inactivate the virus.
Deal Structure: ZMapp is the result of a collaboration between Mapp Biopharmaceutical, and LeafBio (San Diego, CA), Defyrus(Toronto, Canada), the U.S. government and the Public Health Agency of Canada (PHAC).
Additional information available to subscribers only: